ClinicalTrials.gg
RecruitingNCT06806241Updated Jun 24, 2025

Effects of Tranexamic Acid Irrigation on Impacted Third Molar Surgery

An observational study in Bleeding and Tooth Extraction, sponsored by Bezmialem Vakif University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 14 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-24.

Sponsored by Bezmialem Vakif University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
20
Ages
14 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 57 studies in Hemorrhage with a site in Turkey — 10 open to participants now, 11 under way, 5 of them phase 3. Hemorrhage · Turkey.

Planned enrollment
16th of 16
20 · median 73
Started
2025
with 8 others
Observational
16 of 57
4 open now
Primary completion
2026-03
later than 4 of 10 live
Registered
44th of 57
by date
Lead sponsor
5 of 57
Bezmialem Vakif University

Among the 57 studies in Hemorrhage with a site in Turkey, this one is the 16th largest by planned enrollment of the 16 observational ones that give a count, is one of 9 that started in 2025, is one of 16 observational ones, reaches primary completion later than 4 of the 10 other live ones, and was the 44th registered.

Hemorrhage

1,384 studies on the registry are indexed under Hemorrhage; 245 are open to participants now.

Browse Hemorrhage studies →

Open to participants now

10 of the 57 studies in Hemorrhage with a site in Turkey are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 171 Hemorrhage studies recruiting now, 109 (64%) set no upper age limit and 41 (24%) stop at 75 or younger; 26 take children under 18; 21 take healthy volunteers.

This study: 14 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Hemorrhage with a site in Turkey, or all of them as a file.
02

Study summary

Tranexamic acid (TXA) is an effective hemostatic agent used to reduce blood loss and the need for transfusion. It is a relatively safe drug with minimal significant side effects. The most commonly reported complications include nausea, diarrhea, and occasional orthostatic reactions. The increased risk of thromboembolic events associated with the drug is the most serious complication; however, this has not been reported in most clinical studies and remains uncertain. Based on experience from other types of surgeries, tranexamic acid appears to be safe for use without an increased risk of venous thrombosis. To mitigate systemic absorption and minimize undesirable side effects, TXA can be applied topically rather than intravenously, reducing the risk of venous thromboembolism.

Read the detailed description

Topical TXA irrigation has recently begun to be used intraoperatively. In a study conducted by Eftekharian et al., the application of intraoperative 1% TXA irrigation solution during bimaxillary orthognathic surgery was found to be significantly associated with a reduction in intraoperative blood loss compared to placebo. Additionally, the topical application of TXA to the maxillary sinus during endoscopic sinus surgery has been shown to reduce intraoperative blood loss. In the current literature, the use of tranexamic acid irrigation during tooth extraction under local anesthesia has not been reported. Our study aims to demonstrate the effectiveness of TXA irrigation during the extraction of bone-retained teeth and its effect on postoperative edema.

03

Conditions studied

  • Bleeding
  • Tooth Extraction

Browse trials for

Keywords

  • bleeding
  • tranexamic acid
  • wisdom teeth removal
  • edema
04

Who can participate

Ages eligible
14 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

community sample

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Indicated for the Extraction of Bilaterally Impacted Third Molars with Bone Retention.
  2. Systemically healthy patients aged 14-40 years with no bleeding disorders.

Exclusion criteria

Exclusion Criteria:

  1. Patients with systemic diseases affecting general health.
  2. Patients diagnosed with any bleeding disorder.
  3. Patients with advanced infection or cysts associated with the impacted tooth.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
20 participants (estimated)
Target follow-up
3 Days
Patient registry
Yes

Groups and cohorts

  • saline irrigation group

    In the double-blind, controlled, randomized study, only saline will be used as the irrigation solution in the control group patients.

    Drug: saline irrigation

  • tranexamic acid Irrigation group

    In the double-blind, controlled, randomized study, saline with tranexamic acid solution will be used as the irrigation solution in the study group patients.

    Drug: Tranexamic acid

Interventions

  • in the study group, a combination of two ampules of Tranexamic acid solution mixed with saline will be used. Intraoperative bleeding, surgical field visibility, and postoperative edema will be monitored.

  • Drugsaline irrigation

    In control group, saline will be used for irrigation.Intraoperative bleeding, surgical field visibility, and postoperative edema will be monitored.

06

What researchers measure

Primary outcomes

  1. postoperative edema

    Anatomical landmarks, including gonion (Go), ala nasi (AN), tragus (Tr), and lateral canthus (Ka), will be marked with methylene blue for measurement purposes. The distances between lateral canthus and gonion, tragus and commissure, and gonion and ala nasi will be measured preoperatively (just before the procedure begins) and on postoperative day 3, when maximum edema is expected, and the values will be recorded.

    Time frame: 3 days

Secondary outcomes

  1. intraoperative bleeding

    During the surgery, the total aspirate volume collected in the suction device will be recorded. By subtracting the amount of irrigation solution used, the amount of bleeding (in cc) will be calculated separately for the right and left sides and documented.

    Time frame: during the surgery time

  2. intraoperative vision scale

    Intraoperatively, based on the evaluation of surgical bleeding and surgical comfort, the surgeon will be asked to rate the surgical field on a 5-point scale after irrigation. An average score will be calculated postoperatively to determine the surgical field evaluation score. Separate scoring will be performed for both the right and left sides. Scale: 1. \- Intense bleeding, making it impossible to isolate the tooth. 2. \- Severe bleeding, making isolation difficult. 3. \- Moderate bleeding, causing slight difficulty in isolation. 4. \- Mild bleeding, isolation is unaffected. 5. \- No bleeding or an almost bloodless surgical field.

    Time frame: during the surgery

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Mar 2026, 14 months after the start.

Of 134 non-industry observational studies under Hemorrhage, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 78. This study's planned 14 months is below that.

Counting every sponsor, half of 158 studies reached it within 33 months; a quarter within 15 and three quarters within 74.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2025
First posted
Feb 4, 2025
StartActual
Jan 1, 2025
Primary completionEst.
Mar 1, 2026
CompletionEst.
Mar 10, 2026
Last update
Jun 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06806241
Responsible party
Sponsor
First posted
Feb 4, 2025
Start date
Jan 1, 2025
Primary completion
Mar 1, 2026 (estimated)
Completion
Mar 10, 2026 (estimated)
Last update
Jun 24, 2025

Study contacts

Taha Pergel, Asist.Prof
Contact
tahapergel_05@hotmail.com
+902124531850

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion